ABBV vs PFE
ABBV and PFE side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABBVAbbVie Inc. | PFEPFIZER INC |
|---|---|---|
| Market cap | $434.64B | $152.44B |
| P/E (TTM) | 69.5 | 35.2 |
| P/B | — | 1.79 |
| P/S | 7.1x | 2.4x |
| Dividend yield | 2.68% | 6.41% |
| Revenue | $61.16B(TTM) | $63.70B(TTM) |
| Revenue growth (YoY) | 8.6% | -1.6% |
| Net income | $6.31B(TTM) | $4.33B(TTM) |
| Earnings growth (YoY) | -1.2% | -3.2% |
| EPS, diluted | $3.54(TTM) | $0.76(TTM) |
| EBIT margin | 24.6% | 16.3% |
| ROE | — | 9.1% |
| ROIC | 18.6% | 6.9% |
| 1y total return | +27.0% | +17.3% |
Figures from SEC filings · for reference only · not investment advice
Growth of $10,000: ABBV vs PFE
| Metric | ABBV | PFE |
|---|---|---|
| End value | $63.1K | $13.0K |
| Total return | +530.7% | +30.2% |
| CAGR | +19.5% | +2.6% |
| Volatility | 25.8% | 23.8% |
| Sharpe | 0.67 | 0.06 |
| Sortino | 0.94 | 0.09 |
| Max drawdown | -45.1% | -59.0% |
Based on 2600 common trading days, 2016-04-06 → 2026-08-07 · risk-free 3.87% (current short-Treasury, held constant)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)